Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Estetrol therapy in primary Sjögren’s syndrome
NL-OMON22190Phase 2Active, not recruiting
- Sponsor
- EMC Pharma
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of estetrol in primary Sjögren's syndrome, sponsored by EMC Pharma. Primary endpoints: Composite clinical response across Sjögren’s syndrome domains, Oral improvement and 2 more. Started Nov 2008; status: active, not recruiting.
02
Drugs
estetrol
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on NL-OMON22190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22190.